Analyst Josh Jennings from TD Cowen maintained a Buy rating on Alphatec Holdings (ATEC – Research Report) and keeping the price target at ...

CNBC’s Jim Cramer on Friday evaluated the stock of Abbott Laboratories, a healthcare company that’s been weighed down by ...

Abbott Laboratories showcases robust financial performance with a notable increase in net earnings. Strategic acquisitions and product launches strengthen the company's market presence.

So on that note, Abbott Laboratories (NYSE:ABT) looks quite promising in regards to its trends of return on capital. What Is Return On Capital Employed (ROCE)? Just to clarify if you're unsure ...

Is the company still worth a look if you're a long-term investor? Abbott Laboratories is one of the world's leading medical device makers. It routinely develops and markets newer products ...

Abbott Laboratories beat third-quarter profit and sales estimates on strong demand for its medical devices. Sales were also higher at its pharmaceutical unit, but fell at its diagnostics and ...

CNBC's Jim Cramer on Friday evaluated the stock of Abbott Laboratories, a healthcare company that's been weighed down by ongoing litigation for several months. Abbott was cleared Thursday night of ...

Abbott Laboratories ABT will release its quarterly earnings report on Wednesday, 2024-10-16. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Abbott ...

Abbott Laboratories (NYSE:ABT) underwent analysis by 9 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. Summarizing their recent assessments, the table ...

If a company's history and track record were good enough reasons to buy its shares, it'd be easy to make a case for investing ...